Literature DB >> 19636063

A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients.

Andrew J Gentles1, Ash A Alizadeh, Su-In Lee, June H Myklebust, Catherine M Shachaf, Babak Shahbaba, Ronald Levy, Daphne Koller, Sylvia K Plevritis.   

Abstract

Histologic transformation (HT) of follicular lymphoma to diffuse large B-cell lymphoma (DLBCL-t) is associated with accelerated disease course and drastically worse outcome, yet the underlying mechanisms are poorly understood. We show that a network of gene transcriptional modules underlies HT. Central to the network hierarchy is a signature strikingly enriched for pluripotency-related genes. These genes are typically expressed in embryonic stem cells (ESCs), including MYC and its direct targets. This core ESC-like program was independent of proliferation/cell-cycle and overlapped but was distinct from normal B-cell transcriptional programs. Furthermore, we show that the ESC program is correlated with transcriptional programs maintaining tumor phenotype in transgenic MYC-driven mouse models of lymphoma. Although our approach was to identify HT mechanisms rather than to derive an optimal survival predictor, a model based on ESC/differentiation programs stratified patient outcomes in 2 independent patient cohorts and was predictive of propensity of follicular lymphoma tumors to transform. Transformation was associated with an expression signature combining high expression of ESC transcriptional programs with reduced expression of stromal programs. Together, these findings suggest a central role for an ESC-like signature in the mechanism of HT and provide new clues for potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636063      PMCID: PMC2759646          DOI: 10.1182/blood-2009-02-202465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.

Authors:  Emanuela Carlotti; David Wrench; Janet Matthews; Sameena Iqbal; Andrew Davies; Andrew Norton; Jason Hart; Raymond Lai; Silvia Montoto; John G Gribben; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2009-02-06       Impact factor: 22.113

2.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.

Authors:  D M Vigushin; S Ali; P E Pace; N Mirsaidi; K Ito; I Adcock; R C Coombes
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

3.  Diagnosis of multiple cancer types by shrunken centroids of gene expression.

Authors:  Robert Tibshirani; Trevor Hastie; Balasubramanian Narasimhan; Gilbert Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

4.  TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b.

Authors:  J Seoane; C Pouponnot; P Staller; M Schader; M Eilers; J Massagué
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

5.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.

Authors:  José I Martín-Subero; Markus Kreuz; Marina Bibikova; Stefan Bentink; Ole Ammerpohl; Eliza Wickham-Garcia; Maciej Rosolowski; Julia Richter; Lidia Lopez-Serra; Esteban Ballestar; Hilmar Berger; Xabier Agirre; Heinz-Wolfram Bernd; Vincenzo Calvanese; Sergio B Cogliatti; Hans G Drexler; Jian-Bing Fan; Mario F Fraga; Martin L Hansmann; Michael Hummel; Wolfram Klapper; Bernhard Korn; Ralf Küppers; Roderick A F Macleod; Peter Möller; German Ott; Christiane Pott; Felipe Prosper; Andreas Rosenwald; Carsten Schwaenen; Dirk Schübeler; Marc Seifert; Benjamin Stürzenhofecker; Michael Weber; Swen Wessendorf; Markus Loeffler; Lorenz Trümper; Harald Stein; Rainer Spang; Manel Esteller; David Barker; Dirk Hasenclever; Reiner Siebert
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

6.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

8.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors.

Authors:  Michael L Whitfield; Gavin Sherlock; Alok J Saldanha; John I Murray; Catherine A Ball; Karen E Alexander; John C Matese; Charles M Perou; Myra M Hurt; Patrick O Brown; David Botstein
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

9.  Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

Authors:  Seiichi Mori; Rachel E Rempel; Jeffrey T Chang; Guang Yao; Anand S Lagoo; Anil Potti; Andrea Bild; Joseph R Nevins
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.

Authors:  Raphael Margueron; Guohong Li; Kavitha Sarma; Alexandre Blais; Jiri Zavadil; Christopher L Woodcock; Brian D Dynlacht; Danny Reinberg
Journal:  Mol Cell       Date:  2008-11-21       Impact factor: 17.970

View more
  28 in total

1.  A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.

Authors:  Chung-Gi Lee; Bikul Das; Tara L Lin; Chelsea Grimes; Xin Zhang; Tracey Lavezzi; Li Huang; John Cole; Lillian Yau; Li Li
Journal:  Br J Haematol       Date:  2012-04-18       Impact factor: 6.998

Review 2.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

3.  A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Authors:  Chloé B Steen; Ellen Leich; June H Myklebust; Sandra Lockmer; Jillian F Wise; Björn E Wahlin; Bjørn Østenstad; Knut Liestøl; Eva Kimby; Andreas Rosenwald; Erlend B Smeland; Harald Holte; Ole Christian Lingjærde; Marianne Brodtkorb
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

4.  Inherited genetic variation and overall survival following follicular lymphoma.

Authors:  Todd M Gibson; Sophia S Wang; James R Cerhan; Matthew J Maurer; Patricia Hartge; Thomas M Habermann; Scott Davis; Wendy Cozen; Charles F Lynch; Richard K Severson; Nathaniel Rothman; Stephen J Chanock; Lindsay M Morton
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

5.  Sparse expression bases in cancer reveal tumor drivers.

Authors:  Benjamin A Logsdon; Andrew J Gentles; Chris P Miller; C Anthony Blau; Pamela S Becker; Su-In Lee
Journal:  Nucleic Acids Res       Date:  2015-01-12       Impact factor: 16.971

Review 6.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

7.  An animal model of MYC-driven medulloblastoma.

Authors:  Yanxin Pei; Colin E Moore; Jun Wang; Alok K Tewari; Alexey Eroshkin; Yoon-Jae Cho; Hendrik Witt; Andrey Korshunov; Tracy-Ann Read; Julia L Sun; Earlene M Schmitt; C Ryan Miller; Anne F Buckley; Roger E McLendon; Thomas F Westbrook; Paul A Northcott; Michael D Taylor; Stefan M Pfister; Phillip G Febbo; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

Review 8.  Pathogenesis of follicular lymphoma.

Authors:  Robert Kridel; Laurie H Sehn; Randy D Gascoyne
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

9.  The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

Authors:  Andrew G Muntean; Jiaying Tan; Kajal Sitwala; Yongsheng Huang; Joel Bronstein; James A Connelly; Venkatesha Basrur; Kojo S J Elenitoba-Johnson; Jay L Hess
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

10.  Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.

Authors:  Ash A Alizadeh; Sean P Bohen; Chen Lossos; Jose A Martinez-Climent; Juan Carlos Ramos; Elena Cubedo-Gil; William J Harrington; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2010-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.